The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer

摘要

Background: Borderline resectable pancreatic cancer may require extended resections in order to achieve tumor-free margins, especially in the case of up-front resections, but it is important to know the limits of surgical therapy in this disease. This study aimed to investigate the impact of extent of pancreatic and venous resection on short- and long-term outcomes in patients with pancreatic adenocarcinoma (PDAC). Methods: This was a retrospective study from a prospectively maintained database of pancreatic resec-tions for PDAC. Short- and long-term outcomes were analyzed in patients having borderline resectable PDAC submitted to up-front total pancreatectomy (TP) or pancreaticoduodenectomy (PD) with simultane-ous portal vein (PV) and/or superior mesenteric vein (SMV) resection. Venous resections were carried out as tangential venous resection (TVR) or segmental venous resection (SVR). Patients were divided into 4 groups: (1) PD + TVR, (2) PD + SVR, (3) TP + TVR, (4) TP + SVR. Uni- and multivariate Cox regression analysis were performed to identify factors associated with survival. Results: Ninety-nine patients were submitted to simultaneous pancreatic and venous resection for PDAC. Among them, 25 were submitted to PD + TVR (25.3％), 12 to PD + SVR (12.1％), 23 to TP + TVR (23.2％), and 39 to TP + SVR (39.4％). Overall, major morbidity (Clavien-Dindo grade ≥ IIIA) was 26.3％. Thirty- and 90-day mortality were 3％ and 11.1％, respectively. There were no significant differences among groups in terms of short-term outcomes. Median overall survival of patients submitted to PD + TVR was signifi-cantly higher than those to TP+SVR (29.5 vs 7.9 months, P=0.001). Multivariate analysis identified TP (HR = 2.11; 95％ CI: 1.31–3.44; P=0.002) and SVR (HR = 2.01; 95％ CI: 1.27–3.15; P=0.003) as the only independent prognostic factors for overall survival. Conclusions: Up-front TP associated to SVR was predictive of worse survival in borderline resectable PDAC. Perioperative treatments in high-risk surgical groups may improve such poor outcomes.